Aisling Capital Management LP — 13F Holdings

2026 Q3  ·  14 Positions

2026 Q3 Portfolio Activity

In 2026 Q3, Aisling Capital Management LP maintained a portfolio of 14 distinct positions. They heavily accumulated shares in COMPASS PATHWAYS PLC, increasing the position by 20.9%. The fund also reduced its exposure to BRIDGEBIO PHARMA INC by 32.7%.
Position History hover any row below to update
Loading…
Aisling Capital Management LP New York, NY Venture Capital / Life Sciences AUM $299M
PCA Score Concentration Risk
Risk ENB
Total Positions
14
Quarter
2026 Q3
Top Holding
BBIO (67.9%)
Top 10 Concentration
98.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-14 of 14

Aisling Capital Management LP Full Holdings List — 2026 Q3

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
BBIO
BRIDGEBIO PHARM...
Healthcare 67.92% 72.48% #1
Prev: #1
6.0
—
-1,500,000 -32.7%
P
S
3,089,611 $203,296,404 2019 Q2 13F Filing 2026-09-30 2026-11-12
SNDX
SYNDAX PHARMACE...
Healthcare 8.27% 6.10% #2 1
Prev: #3
5.8
—
no change no change
P
S
1,316,806 $24,755,953 2020 Q1 13F Filing 2026-09-30 2026-11-12
CMPS
COMPASS PATHWAY...
Healthcare 7.20% 4.30% #3 1
Prev: #4
6.4
—
300,000 20.9%
P
S
1,732,336 $21,550,260 2023 Q3 13F Filing 2026-09-30 2026-11-12
GLUE
MONTE ROSA THER...
Healthcare 6.20% 7.98% #4 2
Prev: #2
4.0
—
no change no change
P
S
1,555,664 $18,559,072 2021 Q2 13F Filing 2026-09-30 2026-11-12
BCAX
BICARA THERAPEU...
Healthcare 3.41% 3.58% #5
Prev: #5
2.4
—
-20,000 -3.5%
P
S
548,919 $10,215,383 2024 Q3 13F Filing 2026-09-30 2026-11-12
URGN
UROGEN PHARMA L...
Healthcare 1.47% 0.84% #6 2
Prev: #8
1.6
—
no change no change
P
S
108,000 $4,388,040 2025 Q4 13F Filing 2026-09-30 2026-11-12
BBOT
BRIDGEBIO ONCOL...
Healthcare 1.38% 1.64% #7 1
Prev: #6
1.6
—
no change no change
P
S
1,018,018 $4,137,874 2025 Q3 13F Filing 2026-09-30 2026-11-12
EPRX
EUPRAXIA PHARMA...
Healthcare 0.99% 0.46% #8 3
Prev: #11
1.4
—
no change no change
P
S
325,000 $2,957,500 2026 Q1 13F Filing 2026-09-30 2026-11-12
BMEA
BIOMEA FUSION I...
Healthcare 0.92% 0.64% #9
Prev: #9
1.4
—
no change no change
P
S
2,048,757 $2,742,847 2021 Q2 13F Filing 2026-09-30 2026-11-12
ACRS
ACLARIS THERAPE...
Healthcare 0.76% 0.49% #10
Prev: #10
1.3
—
no change no change
P
S
434,455 $2,285,233 2018 Q4 13F Filing 2026-09-30 2026-11-12
SRRK
SCHOLAR ROCK HL...
Healthcare 0.68% 0.90% #11 4
Prev: #7
0.3
—
-35,000 -45.4%
P
S
42,031 $2,030,938 2025 Q3 13F Filing 2026-09-30 2026-11-12
VTVT
VTV THERAPEUTIC...
Healthcare 0.61% 0.40% #12
Prev: #12
2.2
—
8,775 17.5%
P
S
58,775 $1,812,621 2026 Q2 13F Filing 2026-09-30 2026-11-12
MRKR
MARKER THERAPEU...
Healthcare 0.12% 0.10% #13
Prev: #13
1.0
—
no change no change
P
S
325,370 $348,146 2023 Q2 13F Filing 2026-09-30 2026-11-12
OKUR
ONKURE THERAPEU...
Healthcare 0.08% 0.09% #14
Prev: #14
1.0
—
no change no change
P
S
88,607 $241,454 2024 Q4 13F Filing 2026-09-30 2026-11-12
Showing 1-14 of 14 holdings

Unlock Full Aisling Capital Management LP Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →